GeNO

GeNO LLC is a biopharmaceutical company developing next-generation inhaled nitric oxide (NO) products designed to address unmet medical needs in patients with pulmonary and cardiac diseases. The company's proprietary GeNOsyl® drug delivery technology comprises a single-use drug cassette paired with either a portable console or wearable controller,... enabling safe and effective NO delivery across both acute hospital settings and longer-term outpatient applications. GeNO's lead product, GeNOsyl Acute DS, is engineered to deliver a constant intra-breath concentration of therapeutic NO to ventilated patients in hospital environments while also supporting administration via nasal cannula or face mask, with a design emphasis on simplicity and intuitive clinical use. The company was founded on a distinctive scientific insight: conventional NO delivery methods based on dilution of concentrated nitric oxide inevitably produce significant co-delivery of nitrogen dioxide (NO2) due to the non-linear kinetics of NO-oxygen reactions. GeNO's proprietary chemistry addresses this limitation by starting with NO2 and chemically removing one oxygen atom to generate nitric oxide rapidly and quantitatively, thereby minimizing the problematic dilution step and improving safety and efficacy profiles compared to existing NO delivery systems. This chemistry-first approach, developed by founder Dr. David Fine, who brings four decades of expertise in NO and NO2 chemistry, represents a meaningful advancement in inhaled nitric oxide therapeutics. GeNO currently maintains two active Investigational New Drug Applications (INDs) utilizing its nitric oxide delivery system, with clinical studies exploring NO as a diagnostic agent for right heart catheterization in patients with pulmonary arterial hypertension and other therapeutic indications. The company's differentiated technology platform, combined with its focus on user-friendly clinical solutions and rigorous chemical precision, positions GeNO to compete effectively in the inhaled ...Read More